The future of nutrition is personal.
Built on biotic science. Guided by Ridli. Delivered daily.
Confidential · November 2026
The problem
Supplements are built for everyone.
That’s the problem.
In our view, one-size-fits-all formulas are why most people never feel a difference, and why they stop.
Same formula for every body
Generic stacks ignore goals, sensitivities, and routines.
No feedback loop
Nothing changes when life, training, or symptoms change.
No relationship after checkout
Brands sell a bottle, then disappear until the next ad.
The wedge works
Holy Cow!™
I can digest dairy again.
“A bowl of cereal doesn’t result in anywhere near the reaction it used to.”
“I’ve noticed higher tolerance for milk and dairy than before.”

Holy Cow!™ is a once-daily probiotic for lactose digestion support with occasional dairy; it is not a lactase enzyme. Quotes are from verified customers and reflect individual experience.
Traction
Customers buy, come back, and stay.
Operating metrics are management reported. LTV is a company-reported estimate. Retention is a management estimate; cohort and period require reconciliation. Rating is management-reported across all brands.
The science moat
Our edge starts with the strain.
Once-daily lactose digestion support. The focused hero product behind Holy Cow!™ that opens the customer relationship.
A postbiotic candidate for sleep, mood, and stress propositions, and the basis of our next-brand concept.
KGA-10 is subject to evidence, clinical, regulatory, IP, supply, and commercial diligence and launch review. Timing reflects management estimates; future formats remain subject to formulation, claims, and launch review. Pediatric suitability requires review.
The platform
Meet Ridli.
An AI nutrition companion that turns a single product into a personal routine. Text-first, with human guidance when needed.
+
Base 30-count probiotic
+ a monthly personalized sachet

I started with Holy Cow!™. What else can I build on?
Let’s look at your goals and current routine, then explore what may fit alongside your foundational product.
Next month’s pack
- Base 30-count probiotic
- Personalized monthly sachet
Reviewed with human guidance when needed.
Sleep’s been rough this week.
Noted. I’ll factor that into next month’s sachet and check in Friday.
Illustrative conversation. Ridli is not a diagnostic service. Consumer concept available; management reports an existing code foundation, and production readiness requires validation.
How it compounds
One product starts it. Ridli keeps it growing.
Start with the hero
A focused gut or mind foundation customers can feel.
Ask for more
New goals and questions bring Ridli in.
Personalize
Eligible additions, chosen with guidance, in the monthly pack.
Check in
Feedback informs the next routine, and the next order.
Every check-in feeds the next month
Personalization, partner fulfillment, and delivery extensions are proposed architecture, not a verified live integration or a commitment to supply any ingredient. Safety, claims, data consent, catalog availability, and unit economics are launch gates.
Portfolio
One engine. Many brands.

Holy Cow!™
Daily lactose digestion support, growing into a carefully tested family of formats.

Element Longevity
Biotic routines for training and everyday movement, via bike and run stores, clubs, and coaches.

Human Strain
Strain-specific nutrition for practices and clients, with SMS-first onboarding.

Great Brain Day
A NeuroAlly™ KGA-10 opportunity for sleep, mood, and stress.
Great Brain Day is a concept subject to evidence, formulation, and launch review. Product images are illustrative packaging.
Go-to-market
Win the wedge. Scale discovery.
A name built for short-form
A familiar expression and a ready-made creative hook. Creator clips drive discovery; DTC and Amazon handle purchase and replenishment.

Kyan Olshove · 2026 Iceman Cometh Pro Men’s Champion · Element community athlete
Bike + run stores
Specialty-store pilots pair staff education, clubs, and coaches with QR-led AI onboarding.

Practices + practitioners
SMS-first intake, strain education, practitioner review, and private product ordering.
Store pilots and practitioner access are proposed; AI and partner workflows are in development; placements and outcomes are not assumed. Athlete experience is not proof of product efficacy or a guarantee of performance. Race result: 9&10 News, Nov. 9, 2026. Photo: Element Longevity.
Four-year financial path
From $204.5K to $18.43M in net revenue.
($151.6K) net income / (loss)
10 months actual + 2 forecast
($364.4K) net income / (loss)
Forecast
$1.07M net income / (loss)
Forecast
$6.32M net income / (loss)
Forecast
Financial outlook figures are management projections and forward-looking statements, not guarantees. 2026 reflects 10 months of actuals plus 2 months forecast; 2027–2029 are forecasts.
Four-year outcome
Year 4 creates two credible paths to liquidity.
Sell the platform
A strategic acquirer buys the portfolio, differentiated strain access, clinical evidence, customer data, and AI operating system together.
Sell a breakout brand
A category winner such as Holy Cow!™ exits independently while R3VY keeps the engine, science base, and remaining portfolio upside.
Strategic buyers are paying for science, trust, and channel reach
The case is not size parity. It is buyer appetite for differentiated, science-led wellness brands with trusted channels.
2029 value and value-to-cap ratio are illustrative and forward-looking. GRÜNS and Thorne values were publicly reported; Unilever did not disclose the GRÜNS purchase price. Nutrafol reflects €811M converted at the ECB reference rate on July 7, 2022, for a further 67% (total ownership 80%). Bountiful from buyer disclosure.
Team
Operators who have already scaled.

Co-founder & CEO
Haig Newton
Scaled a health-and-wellness startup to $30M in annual revenue. Leads architecture, capital strategy, and AI-native systems.

Co-founder & CMO
Nick Perez
Growth marketer who has scaled consumer brands to tens of millions in revenue. Leads positioning, acquisition, and growth.

CXO
Darren Becket
Leads product strategy, scientific translation, supplier relationships, customer experience, and brand development.

Dr. Shekhar Challa
Lead investor · Board-certified gastroenterologist
The ask
Complete the $1M raise. Fund the next stage.
Closed: $200K direct equity + two $50K SAFEs. Separately, $116,167.96 in founder/partner capital brings total funding to $416,167.96.
Use of funds · Prior six-month spending mix
Use-of-funds percentages reflect the prior six-month spending mix, shown as a guide to how capital is deployed; they are not a commitment for future allocation.
Thank you.
Let’s build the future of personal nutrition.
Built on biotic science. Guided by Ridli. Delivered daily.
Haig Newton
Co-founder & CEO · R3VY
Hero products.
Personal relationships.
One shared platform.
Confidential · Investor discussion · November 2026
Appendix
Notes & disclosures
Confidential. This presentation is for discussion with prospective investors only and is not an offer to sell or a solicitation of an offer to buy securities.
Operating metrics. Direct orders, LTV, CAC, LTV/CAC, peak MoM growth, finished-unit cost, retail product margin, rating, and retention are management reported. LTV is a company-reported estimate. Retention is a management estimate; cohort and period require reconciliation. Margin is at $45 retail before channel costs.
Forward-looking statements. The financial outlook (2026–2029), first profitable month and year, illustrative 2029 value, and value-to-cap ratio are projections and illustrations, not guarantees. 2026 reflects 10 months actual plus 2 months forecast.
Development thesis. New assets, brands, and services are a development thesis, not booked value. NeuroAlly™ KGA-10 remains subject to clinical, regulatory, IP, supply, and commercial diligence. Future formats and timing remain subject to formulation, claims, and launch review; pediatric suitability requires review.
Ridli. Ridli is not a diagnostic service. The consumer concept is available; management reports an existing code foundation, and production readiness and practitioner data isolation require validation. Conversations shown are illustrative.
Personalization and fulfillment. Partner fulfillment and tool-connection layers are proposed architecture, not a verified live integration or a commitment to supply any ingredient. Safety, claims, data consent, catalog availability, and unit economics are launch gates. Prompt and trace value depends on rights, consent, evaluation, and reuse; no standalone valuation is assigned.
Products. Holy Cow!™ is a probiotic, not a lactase enzyme. Customer quotes reflect individual experience. Packaging shown may be illustrative.
Athlete. Athlete experience is not proof of product efficacy or a guarantee of performance. Race result: 9&10 News, Nov. 9, 2026. Photo: Element Longevity.
Comparable transactions. GRÜNS and Thorne values were publicly reported; Unilever did not disclose the GRÜNS purchase price. Nutrafol reflects €811M converted at the ECB reference rate on July 7, 2022; Unilever bought a further 67%, bringing total ownership to 80%. Bountiful comes from buyer disclosure. The valuation case is not size parity.
Use of funds. Percentages reflect the prior six-month spending mix.
© 2026 R3VY. All rights reserved.